pathway

Chaperone

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Chaperone: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

663Connections

5Hypotheses

4Analyses

50Outgoing

50Incoming

Summary

Chaperone is a biological pathway involved in neurodegeneration research. Key relationships include: activates, associated with, regulates. Associated with Aging, Als, Alzheimer. Connected to 377 entities in the SciDEX knowledge graph.

View on Wiki →

🔀 Pathway Info

Name	Chaperone
Summary	Biotechnology company developing autophagy-enhancing therapies for Parkinson's disease through LAMP2A modulation
Key Genes/Proteins	AUTOPHAGY, OXIDATIVE STRESS, NEURODEGENERATION, PARKINSON
Related Diseases	Als, Neurodegeneration, Parkinson, Cancer, Alzheimer
Linked Hypotheses	5 hypotheses

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    ERK["ERK"] -.->|"inhibits"| Chaperone["Chaperone"]
    ERK1["ERK1"] -.->|"inhibits"| Chaperone["Chaperone"]
    HSPA1A["HSPA1A"] -->|"activates"| Chaperone["Chaperone"]
    HSP70["HSP70"] -->|"expressed in"| Chaperone["Chaperone"]
    style Chaperone fill:#1b5e20,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (51)

Target	Relation	Type	Str
Proteins	protects_against	protein	0.50
disease	activates	disease	0.50
PPP3	activates	concept	0.50
Neuroblastoma	activates	disease	0.50
SELECTIVE AUTOPHAGY	activates	concept	0.50
STEM CELLS	activates	concept	0.50
RAPAMYCIN	activates	concept	0.50
PEROXISOME	activates	concept	0.50
Proteins	interacts_with	protein	0.50
CHAPERONE-MEDIATED AUTOPHAGY	interacts_with	concept	0.50
Proteins	activates	protein	0.50
GSK3	activates	concept	0.50
CHAPERONE-MEDIATED AUTOPHAGY	activates	concept	0.50
disease	associated_with	disease	0.50
Proteins	associated_with	protein	0.50
CHAPERONE-MEDIATED AUTOPHAGY	regulates	concept	0.50
disease	inhibits	disease	0.50
SYNUCLEIN	inhibits	concept	0.50
α-SYNUCLEIN	inhibits	concept	0.50
Proteins	inhibits	protein	0.50
NEURONS	expressed_in	concept	0.50
SYNUCLEIN	expressed_in	concept	0.50
LEWY BODY	expressed_in	concept	0.50
α-SYNUCLEIN	expressed_in	concept	0.50
Proteostasis	associated_with	process	0.50
DENDRITE	associated_with	concept	0.50
Proteostasis	regulates	process	0.50
Protein Folding	regulates	pathway	0.50
NEURONS	activates	concept	0.50
DENDRITE	activates	concept	0.50
AUTOPHAGOSOME	activates	concept	0.50
disease	interacts_with	disease	0.50
Protein Folding	interacts_with	pathway	0.50
Proteostasis	activates	process	0.50
AMYLOID-β	interacts_with	concept	0.50
CELL DEATH	associated_with	concept	0.50
Infection	associated_with	disease	0.50
AMYLOID-β	inhibits	concept	0.50
FBXW7	regulates	concept	0.50
FBXW7	activates	concept	0.50
Fatty Liver	interacts_with	disease	0.50
AMYLOID BETA	activates	concept	0.50
SYNUCLEIN	activates	concept	0.50
LEWY BODY	activates	concept	0.50
α-SYNUCLEIN	activates	concept	0.50
ACHE	inhibits	concept	0.50
PARKINSON'S	interacts_with	concept	0.50
ENDOPLASMIC RETICULUM STRESS	inhibits	concept	0.50
ENDOPLASMIC RETICULUM	inhibits	concept	0.50
BREAST CANCER	inhibits	disease	0.50

Incoming (612)

Source	Relation	Type	Str
Als	therapeutic_target	disease	1.00
AUTOPHAGY	regulates	gene	1.00
AUTOPHAGY	activates	gene	1.00
OXIDATIVE STRESS	regulates	gene	1.00
NEURODEGENERATION	regulates	gene	0.90
Neurodegeneration	regulates	disease	0.90
PARKINSON	therapeutic_target	gene	0.90
Parkinson	therapeutic_target	disease	0.90
NEURODEGENERATION	activates	gene	0.90
Cancer	regulates	disease	0.90
Neurodegeneration	activates	disease	0.85
Cancer	therapeutic_target	disease	0.85
Als	regulates	disease	0.85
Als	activates	disease	0.85
Alzheimer	activates	disease	0.85
P62	regulates	gene	0.80
ALZHEIMER	activates	gene	0.80
ALZHEIMER'S DISEASE	activates	gene	0.80
Aging	activates	disease	0.80
NEURODEGENERATIVE DISORDERS	regulates	gene	0.80
OXIDATIVE STRESS	therapeutic_target	gene	0.80
GENES	activates	gene	0.80
LYSOSOME	regulates	gene	0.80
CANCER	regulates	gene	0.80
APOPTOSIS	activates	gene	0.80
ROS	regulates	gene	0.80
Tumor	inhibits	disease	0.80
PARKINSON'S DISEASE	therapeutic_target	gene	0.80
NEURODEGENERATIVE DISEASES	therapeutic_target	gene	0.80
UBIQUITIN	activates	gene	0.80
Cancer	inhibits	disease	0.75
ERK	inhibits	gene	0.70
BAG3	associated_with	gene	0.70
P62	associated_with	gene	0.70
P38	activates	gene	0.70
NRF2	inhibits	gene	0.70
NEURODEGENERATION	implicated_in	gene	0.70
Neurodegeneration	implicated_in	disease	0.70
PARKINSON'S DISEASE	regulates	gene	0.70
PARKINSON	regulates	gene	0.70
Parkinson	regulates	disease	0.70
Fatty Liver	regulates	disease	0.70
Als	interacts_with	disease	0.70
MDM2	therapeutic_target	gene	0.70
P53	therapeutic_target	gene	0.70
CANCER	therapeutic_target	gene	0.70
MITOPHAGY	regulates	gene	0.70
LC3	regulates	gene	0.70
NRF2	regulates	gene	0.70
Tumor	regulates	disease	0.70

Targeting Hypotheses (5)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
ASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis	0.606	neurodegeneration	How does FUS loss-of-function in TAZ reg
APOE4 Allosteric Rescue via Small Molecule Chaperones	0.542	neurodegeneration	APOE4 structural biology and therapeutic
Proteostasis Enhancement via APOE Chaperone Targeting	0.496	neurodegeneration	Mechanistic role of APOE in neurodegener
Chaperone-Mediated APOE4 Refolding Enhancement	0.482	neurodegeneration	APOE4 structural biology and therapeutic
HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor	0.420	neurodegeneration	Protein aggregation cross-seeding across

Mentioning Analyses (4)

Scientific analyses that reference this entity

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591]	Rusmini P, Cortese K, Crippa V, Cristofa	Autophagy	2019	2
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685]	Litvinchuk A, Suh JH, Guo JL, Lin K, Dav	Neuron	2024	1
The cell biology of APOE in the brain. [PMID:37805344]	Windham IA, Cohen S	Trends Cell Biol	2024	1
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317]	Maxine R Nelson, Peng Liu, Ayushi Agrawa	Nature neuroscience	2023	1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485]	Serrano-Pozo A, Das S, Hyman BT	Lancet Neurol	2021	1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456]	Long JM, Holtzman DM	Cell	2019	1
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008]	Yamazaki Y, Zhao N, Caulfield TR, Liu CC	Nat Rev Neurol	2019	1
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188]	Cetindag AC, Schipke CG, Esselmann H, Kr	The journal of prevention of A	2026	0
ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296]	Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha	Frontiers in bioscience (Landm	2026	0
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635]	Thedim M, Hu J, Maher M, Wiener-Kronish	Br J Anaesth	2026	0
Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639]	Bae H, Song Z, Ali A, Sasaki T, Tesi N e	Geroscience	2026	0
Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401]	Stern A, Linial M	Geroscience	2026	0
Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204]	Sang Y, Cao Y, Li S, Quan Y, Wang S et a	Biomaterials	2026	0
Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196]	Lin Z, Xiong J, Zhang F, Zhang H, Zhu M	Mol Ther	2026	0
Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227]	Samudra N, Vemuri M, Weitlauf J	Curr Opin Obstet Gynecol	2026	0
DPP4-regulated endothelial cell ferroptosis modulates atherosclerosis progressio [PMID:41565199]	Zheng L, Liang K, Peng Y, Jin M, Chen X	J Mol Cell Cardiol	2026	0
ApoE-directed CpG nano-immunoadjuvant ameliorates Alzheimer's-like pathology in [PMID:41651379]	Huang X, Sun YY, Qin YR, Chen H, Pan TT	J Control Release	2026	0
Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pa [PMID:41930593]	Yoshida K, Saito N, Takahashi R, Ando S,	J Alzheimers Dis	2026	0
Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR [PMID:41934727]	Li D, Zhang Y, Wang R, Jin L, Cui X et a	Neurotherapeutics	2026	0
Trajectories of frailty, grip strength and gait speed preceding dementia: a nest [PMID:41936045]	Wu Z, Phyo AZZ, Cribb L, Vishwanath S, O	Age Ageing	2026	0

Chaperone

Understanding Entity Pages

Summary

Wiki Pages (21)

Iduna Biotechnology

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Progressive Supranuclear Palsy (PSP)

Novel Therapy Index

Atypical Parkinsonism

Pathway Diagram

Outgoing (51)

Incoming (612)

Targeting Hypotheses (5)

Mentioning Analyses (4)

Does clusterin exacerbate or protect against neuronal death in neurodegeneration

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

Can chaperone enhancement approaches overcome tau seed saturation effects in adv

Related Papers (20)

Chaperone

Understanding Entity Pages

Summary

Wiki Pages (21)

Iduna Biotechnology

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Progressive Supranuclear Palsy (PSP)

Novel Therapy Index

Atypical Parkinsonism

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Alpha-Synuclein Pathology

nimodipine-als

Neuroresilience Mechanisms and Evidence

Therapeutics

NPM1 Gene

Frontotemporal Dementia (FTD) Mechanistic Pathway

CBS/PSP Treatment Rankings

Multiple System Atrophy

nct07165106

PD Cure Roadmap

Mitochondrial Quality Control

GSK-3β in Neurodegeneration

Mitochondrial Dysfunction in Parkinson's Disease

CBS/PSP Clinical Trials Guide

Pathway Diagram

Outgoing (51)

Incoming (612)

Targeting Hypotheses (5)

Mentioning Analyses (4)

Does clusterin exacerbate or protect against neuronal death in neurodegeneration

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

Can chaperone enhancement approaches overcome tau seed saturation effects in adv

Related Papers (20)